291 related articles for article (PubMed ID: 33203698)
1. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
3. Genomic Status of
Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
[TBL] [Abstract][Full Text] [Related]
4. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
7. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
[TBL] [Abstract][Full Text] [Related]
8. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
[TBL] [Abstract][Full Text] [Related]
10. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
Dang I; DeVries GH
J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
12. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.
Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N
Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
16. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
17. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
18. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
[TBL] [Abstract][Full Text] [Related]
19. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
[TBL] [Abstract][Full Text] [Related]
20. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
